Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics

Vanda Pharmaceuticals Inc. (VNDA): $6.24

0.26 (-4.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add VNDA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#58 of 357

in industry

VNDA Price/Volume Stats

Current price $6.24 52-week high $6.76
Prev. close $6.50 52-week low $3.30
Day low $6.23 Volume 1,134,800
Day high $6.67 Avg. volume 1,870,465
50-day MA $5.06 Dividend yield N/A
200-day MA $4.36 Market Cap 363.16M

VNDA Stock Price Chart Interactive Chart >


Vanda Pharmaceuticals Inc. (VNDA) Company Bio


Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The company was founded in 2002 and is based in Washington, the District of Columbia.


VNDA Latest News Stream


Event/Time News Detail
Loading, please wait...

VNDA Latest Social Stream


Loading social stream, please wait...

View Full VNDA Social Stream

Latest VNDA News From Around the Web

Below are the latest news stories about VANDA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vanda Pharmaceuticals fair value estimate is US$4.84 Vanda...

Yahoo | December 8, 2023

Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY® has a proven safe

Yahoo | December 7, 2023

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.

Yahoo | December 5, 2023

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis.

Yahoo | December 4, 2023

One Analyst Thinks Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Revenues Are Under Threat

The analyst covering Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ) delivered a dose of negativity to shareholders today...

Yahoo | November 11, 2023

Read More 'VNDA' Stories Here

VNDA Price Returns

1-mo 13.87%
3-mo 66.40%
6-mo 56.78%
1-year -1.58%
3-year -68.08%
5-year -57.44%
YTD 47.87%
2023 -42.90%
2022 -52.90%
2021 19.41%
2020 -19.93%
2019 -37.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!